Brinavess

Pajjiż: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Vernakalant hydrochloride 20 mg/mL Equivalent to 18.1 mg/mL of vernakalant

Disponibbli minn:

Merck Sharp & Dohme (New Zealand) Limited

INN (Isem Internazzjonali):

Vernakalant hydrochloride 20 mg/mL (Equivalent to 18.1 mg/mL of vernakalant)

Dożaġġ:

20 mg/mL

Għamla farmaċewtika:

Concentrate for infusion

Kompożizzjoni:

Active: Vernakalant hydrochloride 20 mg/mL Equivalent to 18.1 mg/mL of vernakalant Excipient: Citric acid monohydrate Sodium chloride Sodium hydroxide Water for injection

Unitajiet fil-pakkett:

Vial, glass, Type I with 20 mm chlorobutyl rubber stupper and 20 mm Al overseal with plastic flip off cap, 30 mL, 25 mL

Klassi:

Prescription

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

Merck & Cie

Indikazzjonijiet terapewtiċi:

Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults · For non-surgery patients: atrial fibrillation less than or equal to 7 days duration · For post-cardiac surgery patients: atrial fibrillation less than or equal to 3 days duration

Sommarju tal-prodott:

Package - Contents - Shelf Life: Vial, glass, Type I with 20 mm chlorobutyl rubber stupper and 20 mm Al overseal with plastic flip off cap, 30 mL - 25 mL - 36 months from date of manufacture stored at or below 30°C

Data ta 'l-awtorizzazzjoni:

2009-11-12